DA-1726 is under clinical development by NeuroBo Pharmaceuticals and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DA-1726’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DA-1726 overview
DA-1726 under development for the treatment of the treatment of type 2 diabetes mellitus, non alcoholic steatohepatitis and obesity. It is administered through subcutaneous route. The drug candidate comprises of oxyntomodulin analogue targets glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR).
NeuroBo Pharmaceuticals overview
NeuroBo Pharmaceuticals (NeuroBo), a subsidiary of Dong-A ST Co Ltd, is a biotechnology company. It develops innovative drugs for cardiometabolic diseases. The company’s product pipeline includes DA-1241, a once-daily oral G-protein-coupled receptor 119 (GPR119) agonist currently in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and DA-1726, a novel dual oxyntomodulin (OXM) analog designed for once-a-week injection that acts as an agonist for both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). It is also evaluating ANA001, an oral niclosamide formulation for moderate COVID-19; NB-01 for painful diabetic neuropathy (PDN); NB-02, which targets cognitive impairment; and Gemcabene, aimed at treating dyslipidemia. NeuroBo is headquartered in Boston, Massachusetts, the US.
For a complete picture of DA-1726’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
